vimarsana.com

Latest Breaking News On - Ratio therapeutics - Page 3 : vimarsana.com

Ratio Therapeutics announces first patient dosed in FAP-targeted radiopharmaceutical study

Boston-based pharma company Ratio Therapeutics has initiated dosing in a phase 1 study evaluating the pharmacokinetics, biodistribution and radiation dosimetry of a novel fibroblast activation protein-alpha (FAP)-targeted radiopharmaceutical, RTX-1363S, for PET imaging in adult healthy volunteers.

First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

A collaboration to advance development of a fibroblast activation protein (FAP)-targeted PET diagnostic compound for a broad array of epithelial-derived cancers

vimarsana © 2020. All Rights Reserved.